Skip to main content

HomeLegalRetatrutide in Florida

Educational — Not Legal AdviceUpdated

Retatrutide in Florida: Legal Status & Provider Guide (2026)

Quick Answer

Retatrutide is a prescription substance in the United States. Retatrutide is an investigational triple-receptor agonist (GIP/GLP-1/glucagon) with no FDA approval. It cannot legally be compounded under federal law. Commercial availability outside of clinical trials is not authorized by the FDA. In Florida, compounding is governed by the Florida Board of Pharmacy (FBP). In Florida, advanced practice registered nurses (APRNs) with prescriptive authority and physician assistants may prescribe compounded peptides within the scope of their collaborative agreement. Florida's telehealth laws permit prescribing without prior in-person visit in many contexts, which has made Florida a hub for telehealth peptide programs. Prescribers must hold a Florida license to prescribe to Florida patients.

Federal Legal Status

FDA Approval Status

Not FDA-approved. Retatrutide is in Phase III clinical trials as of 2026. No NDA filed.

Compounding Pharmacy Rules (Federal)

Retatrutide is not FDA-approved and is not on any bulk substances list for compounding. It is an investigational drug in active Phase III trials. Compounding pharmacies cannot legally compound retatrutide under federal law. Providers offering it outside of a formal clinical trial operate without federal regulatory authorization.

Also Known As

LY3437943

Primary Research Areas

  • Weight loss
  • Obesity management
  • Metabolic syndrome
  • Type 2 diabetes

Florida Pharmacy Board & Compounding Rules

Compounding Overview

Florida has a large and active compounding pharmacy sector. The Florida Board of Pharmacy (Department of Health) regulates sterile and non-sterile compounding, requiring separate permits for each type. Florida pharmacies that compound sterile preparations must comply with USP 797 and undergo periodic inspections. Florida has specific rules for "office use" compounding — a provision that allows prescribers to order pre-mixed sterile compounds for use in their offices, which is relevant to many peptide clinics.

Notable Rules

  • Florida requires separate permits for sterile and non-sterile compounding.
  • Florida allows "office use" compounding with specific restrictions — relevant to many peptide clinical practices.
  • USP 797 compliance is mandatory for all sterile compounding facilities.
  • Florida telehealth laws are permissive by national standards, making the state a major market for telehealth peptide programs.
  • Out-of-state pharmacies must be registered with the Florida Board of Pharmacy to ship into the state.

Prescribing Requirements in Florida

In Florida, advanced practice registered nurses (APRNs) with prescriptive authority and physician assistants may prescribe compounded peptides within the scope of their collaborative agreement. Florida's telehealth laws permit prescribing without prior in-person visit in many contexts, which has made Florida a hub for telehealth peptide programs. Prescribers must hold a Florida license to prescribe to Florida patients.

About Retatrutide

Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. Phase II trials reported average weight loss of approximately 24% at the highest dose over 48 weeks. Phase III trials are ongoing as of 2026.

For more research information, mechanism of action, and provider availability, see the Retatrutide research profile on PeptideBase.

Frequently Asked Questions

Is retatrutide available to the public?
Retatrutide is not FDA-approved and is not legally available outside of clinical trials. Some providers may offer it under research or "off-label investigational" frameworks, but this carries significant legal and safety risk. Verify any provider's authorization carefully.
When might retatrutide receive FDA approval?
Phase III trials are ongoing as of 2026. FDA approval, if granted, would follow Phase III completion and NDA review — typically 1–3 years after Phase III initiation. Monitor ClinicalTrials.gov for updates.

Retatrutide Providers in Florida

5 providers in the PeptideBase directory offer Retatrutide in Florida. Always verify current offerings directly with the provider.

Retatrutide Legal Status in Other States

Pharmacy board rules and compounding regulations vary by state. Compare Retatrutide legal status across other major markets:

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.

Free Guide

The Peptide Research Digest

Get our free provider vetting guide — plus weekly research briefings on peptide sourcing, COA verification, and clinical developments.

No spam.